Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis

References

• Sones M, Israel HL, Dratman MB, et al. Effect of cortisone in sarcoidosis. N Engl J Med. 1951;244(6):209–213.
   PubMed Web of Science ®Google Scholar
• James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11(7):677–687.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109–1116.
   PubMed Web of Science ®Google Scholar
• Cozier YC. Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions. Eur Respir J. 2016;48(6):1545–1548.
   PubMed Web of Science ®Google Scholar
• Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29–32.
   PubMedGoogle Scholar
• Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):46–52.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–1252.
   PubMed Web of Science ®Google Scholar
• Dumas O, Abramovitz L, Wiley AS, et al. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc. 2016;13(1):67–71.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: a population-based nested case-control study. Respir Med. 2016;120:87–90.
   PubMed Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165–1172.
   PubMed Web of Science ®Google Scholar
• Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008;177(3):330–336.
   PubMed Web of Science ®Google Scholar
• Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987;20(3):213–219.
   PubMed Web of Science ®Google Scholar
• Rohrbach MS, Deremee RA. Serum angiotensin converting enzyme activity in sarcoidosis as measured by a simple radiochemical assay. Am Rev Respir Dis. 1979;119(5):761–767.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Carmona EM, Crowson CS, et al. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–95.
   PubMed Web of Science ®Google Scholar
• Silverstein E, Friedland J, Kitt M, et al. Increased serum angiotensin converting enzyme activity in sarcoidosis. Isr J Med Sci. 1977;13(10):995–1000.
   PubMedGoogle Scholar
• Rothkrantz-Kos S, van Dieijen-visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49(9):1510–1517.
   PubMed Web of Science ®Google Scholar
• Thi Hong Nguyen C, Kambe N, Kishimoto I, et al. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol. 2017;44(7):789–797.
   PubMed Web of Science ®Google Scholar
• Uysal P, Durmus S, Sozer V, et al. YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity. Biomolecules. 2018;8(3):84.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, van Moorsel CH, Zanen P, et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med. 2015;109(2):279–285.
   PubMed Web of Science ®Google Scholar
• Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):87–94.
   PubMed Web of Science ®Google Scholar
• Akaike G, Itani M, Shah H, et al. PET/CT in the diagnosis and workup of sarcoidosis: focus on atypical manifestations. Radiographics. 2018;38(5):1536–1549.
   PubMed Web of Science ®Google Scholar
• Freemer M, King TE Jr. The ACCESS study: characterization of sarcoidosis in the United States. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1754–1755.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Palmieri G, Agrati AM, et al. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(2):119–126.
   PubMed Web of Science ®Google Scholar
• James WE, Koutroumpakis E, Saha B, et al. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest. 2018;154(2):349–356.
   PubMed Web of Science ®Google Scholar
• Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220.
   PubMedGoogle Scholar
• Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–376.
   PubMedGoogle Scholar
• Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167–172.
   PubMed Web of Science ®Google Scholar
• Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275–280.
   PubMed Web of Science ®Google Scholar
• Manz HJ. Pathobiology of neurosarcoidosis and clinicopathologic correlation. Can J Neurol Sci. 1983;10(1):50–55.
   PubMed Web of Science ®Google Scholar
• Waxman JS, Sher JH. The spectrum of central nervous system sarcoidosis. A clinical and pathologic study. Mt Sinai J Med. 1979;46(3):309–317.
   PubMedGoogle Scholar
• Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149(4 Pt 1):893–898.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15(1):52–58.
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51(3):238–247.
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99(5):307–315.
   PubMed Web of Science ®Google Scholar
• Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–985.
   PubMed Web of Science ®Google Scholar
• Rossides M, Kullberg S, Askling J, et al. Sarcoidosis mortality in Sweden: a population-based cohort study. Eur Respir J. 2018;51(2):1701815.
   PubMed Web of Science ®Google Scholar
• Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest. 2018;153(1):105–113.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–1530.
   PubMed Web of Science ®Google Scholar
• Kearney GD, Obi ON, Maddipati V, et al. Sarcoidosis deaths in the United States: 1999–2016. Respir Med. 2018;149:30–35.
   PubMedGoogle Scholar
• Hanley A, Hubbard RB, Navaratnam V. Mortality trends in asbestosis, extrinsic allergic alveolitis and sarcoidosis in England and Wales. Respir Med. 2011;105(9):1373–1379.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. 2016;48(6):1700–1709.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–581.
   PubMed Web of Science ®Google Scholar
• Judson MA. The treatment of pulmonary sarcoidosis. Respir Med. 2012;106(10):1351–1361.
   PubMed Web of Science ®Google Scholar
• Baughman R. The indications for the treatment of sarcoidosis: wells law. Sarcoidosis Vasculitis Diffuse Lung Dis. 2017;34:280–282.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010;339(1):1–4.
   PubMed Web of Science ®Google Scholar
• Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115(4):1158–1165.
   PubMed Web of Science ®Google Scholar
• Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–531.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. The sarcoidosis health questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168(3):323–329.
   PubMed Web of Science ®Google Scholar
• Victorson DE, Choi S, Judson MA, et al. Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res. 2014;23(4):1301–1313.
   PubMed Web of Science ®Google Scholar
• Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017;132:9–14.
   PubMed Web of Science ®Google Scholar
• Eule H, Weinecke A, Roth I, et al. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. Ann N Y Acad Sci. 1986;465:695–701.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med. 2009;179(4):307–312.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, et al. Finnish pulmonary sarcoidosis study G. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121(1):24–31.
   PubMed Web of Science ®Google Scholar
• Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med. 2018;138S:S31–S37.
   PubMedGoogle Scholar
• Judson MA. Corticosteroids in sarcoidosis. Rheum Dis Clin North Am. 2016;42(1):119–135, ix.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545–561.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   PubMedGoogle Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Caporali R, Todoerti M, et al. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369–378.
   PubMed Web of Science ®Google Scholar
• Todoerti M, Maglione W, Bernero E, et al. Systematic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo. 2013;65(5):207–218.
   PubMedGoogle Scholar
• Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;142(5):e1S–e111S.
   PubMed Web of Science ®Google Scholar
• Grosen A, Kelsen J, Hvas CL, et al. The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure. Inflamm Bowel Dis. 2017;23(4):561–569.
   PubMed Web of Science ®Google Scholar
• Price S, James C, Deighton C. Methotrexate use and alcohol. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S114–116.
   PubMed Web of Science ®Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–1104.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford). 2019;58(11):1900–1906.
   PubMed Web of Science ®Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):e028466.
   PubMed Web of Science ®Google Scholar
• Golicki D, Newada M, Lis J, et al. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn. 2012;122(1–2):22–32.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–48.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150.
   PubMed Web of Science ®Google Scholar
• Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123–1134.
   PubMed Web of Science ®Google Scholar
• Martin N, Innes JA, Lambert CM, et al. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol. 2007;34(9):1934–1937.
   PubMed Web of Science ®Google Scholar
• Laub M, Fraser R, Kurche J, et al. Use of a cholestyramine washout in a patient with septic shock on leflunomide therapy: a case report and review of the literature. J Intensive Care Med. 2016;31(6):412–414.
   PubMed Web of Science ®Google Scholar
• Wong SP, Chu CM, Kan CH, et al. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol. 2009;15(8):389–392.
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812.
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–1122.
   PubMed Web of Science ®Google Scholar
• Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015;9(7):891–900.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–858e844; quiz e848–850.
   PubMed Web of Science ®Google Scholar
• Natekar A, Pupco A, Bozzo P, et al. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57(12):1401–1402.
   PubMed Web of Science ®Google Scholar
• Alami Z, Agier MS, Ahid S, et al. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie. 2018;73(3):199–207.
   PubMed Web of Science ®Google Scholar
• Garritsen FM, van den Broek MPH, van Zuilen AD, et al. Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic. Br J Dermatol. 2017;176(4):866–877.
   PubMed Web of Science ®Google Scholar
• Wan Y. TPMT testing before azathioprine therapy? Drug Ther Bull. 2009;47(1):9–12.
   PubMedGoogle Scholar
• Dean L. Azathioprine therapy and TPMT genotype. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012. Available from: Available from: https://www.ncbi.nlm.nih.gov/books/NBK100661/
   Google Scholar
• Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant. 2006;20(Suppl 17):25–29.
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Schold JD, Meier-Kriesche HU. Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Rev Clin Immunol. 2006;2(4):495–518.
   PubMedGoogle Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619–625.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssen A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383.
   PubMed Web of Science ®Google Scholar
• Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–1172.
   PubMed Web of Science ®Google Scholar
• Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–2521.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–1832.
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castaneda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17(3):185–190.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lower EE, Li HP, et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest. 2017;151(1):139–148.
   PubMed Web of Science ®Google Scholar
• Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24(9):645–663.
   PubMed Web of Science ®Google Scholar
• Gardiner KM, Tett SE, Staatz CE. Is conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium justifiable for gastrointestinal quality of life? Drugs R D. 2018;18(4):271–282.
   PubMed Web of Science ®Google Scholar
• Vento M, Perez Aytes A, Ledo A, et al. Mycophenolate mofetil during pregnancy: some words of caution. Pediatrics. 2008;122(1):184–185.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, D’Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008;7(3):219–222.
   PubMed Web of Science ®Google Scholar
• O’Leary TJ, Jones G, Yip A, et al. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med. 1986;315(12):727–730.
   PubMed Web of Science ®Google Scholar
• Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British tuberculosis association. Tubercle. 1967;48(4):257–272.
   PubMedGoogle Scholar
• Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192–197.
   PubMed Web of Science ®Google Scholar
• Zic JA, Horowitz DH, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol. 1991;127(7):1034–1040.
   PubMedGoogle Scholar
• Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361–1383.
   PubMed Web of Science ®Google Scholar
• Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018;30(3):249–255.
   PubMed Web of Science ®Google Scholar
• Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–1460.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, et al. American Academy of O. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Ther Adv Neurol Disord. 2014;7(2):83–96.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Barney JB, O’Hare L, et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets. 2010;14(1):21–29.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar Inflectra((R)) in severe sarcoidosis. Respir Med. 2018;138S:S7–S13.
   PubMedGoogle Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189–1196.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053–2059.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):143–149.
   PubMed Web of Science ®Google Scholar
• Jounieaux F, Chapelon C, Valeyre D, et al. Infliximab treatment for chronic sarcoidosis – a case series. Rev Mal Respir. 2010;27(7):685–692.
   PubMed Web of Science ®Google Scholar
• Aguiar M, Marcal N, Mendes AC, et al. Infliximab for treating sarcoidosis patients, Portuguese experience. Rev Port Pneumol. 2011;17(2):85–93.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83(3):218–224.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–185.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288–294.
   PubMed Web of Science ®Google Scholar
• Sodhi M, Pearson K, White ES, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2009;103(2):268–273.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89(20):2092–2100.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(4):289–295.
   PubMed Web of Science ®Google Scholar
• Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017;153(7):681–685.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43(1):7–11.
   PubMed Web of Science ®Google Scholar
• Tavee JO, Karwa K, Ahmed Z, et al. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017;126:135–138.
   PubMed Web of Science ®Google Scholar
• Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80(3):212–219.
   PubMed Web of Science ®Google Scholar
• Atkins C, Wilson AM. Managing fatigue in sarcoidosis – a systematic review of the evidence. Chron Respir Dis. 2017;14(2):161–173.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608.
   PubMed Web of Science ®Google Scholar
• Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77.
   PubMed Web of Science ®Google Scholar
• Minnis PA, Poland M, Keane MP, et al. Adalimumab for refractory pulmonary sarcoidosis. Ir J Med Sci. 2016;185(4):969–971.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46–54.
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773.
   PubMed Web of Science ®Google Scholar
• Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: new diagnostic modalities and treatment. Curr Opin Pulm Med. 2017;23(5):458–467.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol. 2013;40(1):74–79.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory Uveitis: a multicenter study from the French Uveitis network. Arthritis Rheumatol. 2016;68(6):1522–1530.
   PubMed Web of Science ®Google Scholar
• Quistrebert J, Hassler S, Bachelet D, et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis. Semin Arthritis Rheum. 2019;48(6):967–975.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–1307.
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062–1067.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics. 2015;9:1–6.
   PubMedGoogle Scholar
• Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–886.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol. 2009;36(11):2421–2427.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913–920.
   PubMed Web of Science ®Google Scholar
• Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–570.
   PubMed Web of Science ®Google Scholar
• Dasilva V, Breuil V, Chevallier P, et al. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine. 2010;77(1):82–83.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol. 2012;6:1613–1618.
   PubMedGoogle Scholar
• Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci. 2013;20(8):1156–1158.
   PubMed Web of Science ®Google Scholar
• Kamphuis LS, van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med. 2013;187(4):406–416.
   PubMed Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.
   PubMedGoogle Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546.
   PubMed Web of Science ®Google Scholar
• Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980;78(1):36–43.
   PubMed Web of Science ®Google Scholar
• Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis. 1991;8(1):35–41.
   PubMedGoogle Scholar
• Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157(16):1864–1868.
   PubMedGoogle Scholar
• Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest. 1988;94(1):202–203.
   PubMed Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–1669.
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975–994.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229.
   PubMed Web of Science ®Google Scholar